Kenvue Inc. (KVUE) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is not a demanding bar, organic growth is expected to inflect positively for the second consecutive quarter, and the stock is effectively a merger-arb trade anchored to the $21.01 Kimberly-Clark offer. The biggest swing factor is whether Skin Health & Beauty can sustain its Q1 momentum and whether Self Care recovers from a weak cold/flu season.

Heading into Q2 2026, Kenvue's setup is defined more by the pending Kimberly-Clark merger than by fundamental earnings dynamics. Consensus expects net sales of ~$3.96B (+3.2% YoY) and adjusted diluted EPS of ~$0.31, implying a modest but achievable bar after Q1 2026 delivered a clean beat on both revenue and EPS. Management has suspended forward guidance entirely due to the pending transaction, removing the typical guidance-vs.-consensus tension, but Q1's tone was encouraging: CEO Kirk Perry cited "net and organic sales growth for the second consecutive quarter" with meaningful margin improvement. Estimate revisions have been broadly stable since the Q1 print — the Q2 EPS consensus has drifted only marginally (~$0.313 to ~$0.312), suggesting the Street is not pricing in meaningful upside or downside. The stock has re-rated ~11% higher since the Q1 earnings date (May 7), driven almost entirely by multiple expansion and merger-arb compression rather than fundamental revision, and now trades at ~$19.67, still a ~6% discount to the $21.01 deal price. The key wildcard is tariff and input cost pass-through: peers Colgate-Palmolive and P&G both flagged higher raw material and tariff headwinds in 2H 2026, which could pressure KVUE's gross margin trajectory even as productivity savings from the 2026 Restructuring Initiative provide an offset.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar — organic sales growth of ~+2.5% is achievable given Q1's +0.7% and improving category trends, while the adjusted EPS estimate of ~$0.31 sits well below Q1's $0.32 beat. Skin Health & Beauty organic growth is the bigger swing factor; Self Care faces a tougher comp but benefits from a normalized cold/flu season.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 5, 2026. Guidance suspended by management due to pending Kimberly-Clark acquisition announced November 2, 2025.

Table 2 — Beat/Miss History (Last 8 Quarters) — Net Sales & Adj. Diluted EPS

Pattern: KVUE has beaten adjusted EPS consensus in 7 of the last 8 quarters, often by a wide margin — the Street has consistently set a low bar on profitability. Revenue is more mixed (4 beats, 4 misses over 8 quarters), with misses concentrated in periods of organic sales decline (Q3–Q4 2024, Q2–Q3 2025). The recent trend has improved: Q4 2025 and Q1 2026 both beat on revenue, suggesting the top-line bar is now more appropriately calibrated.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Kenvue has suspended all forward guidance due to the pending Kimberly-Clark transaction — there is no initial or revised guidance to track. The last substantive management commentary came from the Q1 2026 earnings release (May 7, 2026), where tone was constructive: CEO Perry highlighted two consecutive quarters of organic growth and expressed confidence in navigating macro uncertainty while completing the KMB combination.

Management Tone (Q1 2026 Earnings Release, May 7, 2026): CEO Kirk Perry: "Our year is off to an encouraging start, as our continued efforts to strengthen the business and sharpen execution resulted in delivering net and organic sales growth for the second consecutive quarter, along with meaningful year-over-year improvement in gross margin, operating margin, and EPS." Perry also noted confidence in "navigating ongoing macro uncertainty" while accelerating the KMB combination. Tone is constructively pragmatic — no earnings call was hosted, limiting the usual Q&A color.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: With no guidance to anchor against, the revision tracker focuses purely on how Street estimates have moved since the Q1 2026 print. Estimates have been remarkably stable — Q2 2026 revenue and EPS consensus are essentially unchanged from the post-Q1 baseline, suggesting the Street is comfortable with the current trajectory but not inclined to chase upside.

Estimates are essentially flat since the Q1 2026 print — the Street has not revised meaningfully in either direction. This stability reflects the merger-arb dynamic: with the stock anchored to the $21.01 deal price, fundamental estimate revisions have limited stock price impact, reducing analyst incentive to update models aggressively. The absence of guidance removes the typical catalyst for revision. The slight downward drift in organic sales growth consensus (-10 bps) may reflect peer commentary on category softness in May (Colgate noted a "significant drop in North America categories in May"), though June showed recovery.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: KVUE has outperformed both XLP and the S&P 500 since the Q1 2026 earnings date (May 7, 2026), gaining ~+11% vs. XLP +1.6% and SPY +5.2% (indexed). The outperformance is driven almost entirely by merger-arb compression toward the $21.01 KMB deal price, not fundamental estimate revisions, which have been flat. The stock is now trading at ~$19.67, a ~6% discount to deal value.

Indexed Performance Since May 7, 2026 (Base = 100):

KVUE +11.0% | XLP (Consumer Staples ETF) +1.6% | SPY (S&P 500) +5.2% — since May 7, 2026.

Key observations: (1) KVUE's outperformance vs. XLP is almost entirely merger-arb driven — the stock has been grinding toward the $21.01 KMB deal price as deal certainty has increased (HSR cleared Feb 4, shareholder votes passed Jan 29). (2) XLP has been a mild underperformer vs. SPY, consistent with peer commentary on category softness in May and tariff/input cost headwinds flagged by CL and PG. (3) KVUE's beta to the broader market has compressed significantly since the merger announcement — the stock now trades more like a fixed-income instrument than a consumer staples equity. (4) The ~6% remaining discount to deal price ($21.01) reflects residual regulatory risk (foreign approvals pending) and time value.

Source: Stock Price Data (Yahoo Finance). Sector ETF: XLP (Consumer Staples Select Sector SPDR Fund), appropriate for KVUE's consumer health/staples sub-sector.

6. Material News & Developments

Key Takeaway: The most important development since the Q1 2026 print is the continued progression of the Kimberly-Clark merger toward closing — all major domestic milestones have been cleared, and the deal is now pending only foreign regulatory approvals. Operationally, the 2026 Restructuring Initiative is the key earnings-relevant development, expected to deliver $250M in pre-tax charges in FY2026 while driving supply chain savings.

• May 7, 2026 — Q1 2026 Earnings Release (Beat): KVUE reported Q1 2026 net sales of $3.909B (+4.5% reported, +0.7% organic) and adj. EPS of $0.32 (+33% YoY), beating consensus on both metrics. Adj. gross margin expanded 80 bps to 60.8%. No earnings call hosted. Implication: Clean beat removes near-term downside risk; sets a constructive tone for Q2.
• February 17, 2026 — 2026 Restructuring Initiative Approved: Board approved a restructuring initiative targeting operating model optimization, supply chain transformation, and complexity reduction. Expected to result in ~$250M in pre-tax charges in FY2026. Implication: Near-term EPS headwind from charges, but medium-term margin tailwind; savings already visible in Q1 SG&A reduction.
• January 29, 2026 — Shareholder Votes Approved: Both KVUE and KMB shareholders overwhelmingly approved all proposals necessary for the merger at their respective Special Meetings. Implication: Removes a key deal risk; deal now pending only foreign regulatory approvals.
• February 4, 2026 — HSR Waiting Period Expired: The Hart-Scott-Rodino antitrust waiting period expired without challenge, clearing the U.S. antitrust hurdle. Implication: Significant de-risking of the deal; remaining risk is foreign regulatory approvals.
• November 2, 2025 — Kimberly-Clark Definitive Merger Agreement: KVUE entered into a definitive merger agreement with Kimberly-Clark at $21.01/share in a cash-and-stock transaction (46% premium to pre-announcement price). Deal expected to close 2H 2026. Implication: Stock is now a merger-arb instrument; fundamental earnings results matter primarily for deal certainty signaling.
• Ongoing — Tariff & Input Cost Environment: Peers CL and PG flagged higher raw material and tariff headwinds in 2H 2026. KVUE's Q1 release noted that productivity gains "more than offset the impact from inflation, tariffs, and lower volumes." Implication: Tariff pass-through is a watch item for Q2 gross margin; KVUE's supply chain optimization program is the key offset.
• Ongoing — Cold/Flu Season Normalization: Q1 2026 Self Care was weighed down by weak cold/flu seasons across major markets. Q2 typically benefits from allergy season (Zyrtec became first Official Allergy Relief Sponsor of PGA TOUR). Implication: Self Care organic growth should improve sequentially in Q2 vs. Q1's -2.3%.

7. Insider Transaction Activity

Key Takeaway: Only one open-market transaction was filed since the Q1 2026 earnings date — a discretionary sale by the General Counsel shortly after the Q1 print. No open-market buys were filed. Given the pending merger at a fixed price, insider buying would be unusual; the single sale is not a meaningful signal.

No other open-market buys or sells (Form 4 codes P/S) were filed in the period from May 7 to August 5, 2026. The absence of insider buying is expected given the pending merger at a fixed price — insiders have limited incentive to purchase shares trading at a discount to a known deal price, and doing so could raise regulatory concerns. The single sale by the General Counsel, who reduced his position to zero, is consistent with pre-merger liquidity management rather than a negative fundamental signal.

Source: SEC Form 4 Filings Database.

8. Peer Commentaries & Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from Colgate-Palmolive (CL), Procter & Gamble (PG), Church & Dwight (CHD), and Newell Brands (NWL) — all reporting Q2 2026 results in late July 2026 — paints a picture of improving but uneven consumer demand: category softness in May rebounded in June, tariff/input cost headwinds are peaking in 2H, and volume-led growth is replacing price-led growth. These dynamics are broadly constructive for KVUE's Q2 organic sales trajectory but flag gross margin risk in 2H.

Note: Only forward-looking commentary applicable to Q2 2026 or beyond, or commentary disclosed after KVUE's last earnings (May 7, 2026), is included below. Purely backward-looking peer results have been excluded.

Colgate-Palmolive (CL) — Q2 2026 Earnings Call (July 31, 2026)

Relevance to KVUE: CL competes directly with KVUE in oral care (Listerine vs. Colgate), personal care, and emerging markets. CL's commentary on North America category dynamics, tariff headwinds, and consumer behavior is highly relevant to KVUE's Self Care and Skin Health & Beauty segments.

• North America Category Softness in May, Recovery in June: "We obviously talked about the significant drop in the North America categories in May. They did come back in June, but still below historical numbers." CL attributed the May weakness to higher gasoline prices and consumer uncertainty. For the back half, CL assumes "more or less sustained" category dynamics based on June/early July trends, not anticipating significant inflection. KVUE Read-Through: Q2 2026 spans April–June, so the May softness and June recovery are directly in-period. KVUE's Self Care segment (Tylenol, Zyrtec, Nicorette) is exposed to the same North America category dynamics. The net effect for Q2 is likely modest — May weakness partially offset by June recovery.
• Volume-Led Growth Replacing Price-Led Growth: CL expects to be "a little bit more volume driven in the back half of this year" compared to the first half, which saw significant pricing. This shift reflects a more competitive promotional environment and the need to drive brand penetration. KVUE Read-Through: KVUE's Q1 2026 organic growth was already price-led (+1.0% value realization, -0.3% volume). A shift toward volume-led growth in the industry could pressure KVUE's pricing power in Q2 and 2H, particularly in Self Care where Tylenol faces private-label competition.
• Tariff & Input Cost Headwinds Peaking in 2H: CL expects "higher raw materials and tariffs will be higher in the second half of the year than they were in second quarter" and that "cost of goods [will] peak in the back half of this year as well as tariffs." CL raised its full-year gross margin guidance to "roughly flat" (from previously expected down), driven by strong execution. KVUE Read-Through: KVUE's Q1 gross margin expansion (+80 bps adj.) was driven by productivity gains offsetting inflation and tariffs. CL's commentary suggests the tariff headwind intensifies in 2H — KVUE's 2026 Restructuring Initiative savings will need to accelerate to maintain margin trajectory.
• Retailer Inventory Adjustments: "As the market softened in May, retailers took note of that and adjusted inventories." CL noted increased couponing and promotion, and does not expect retailers to reload inventory. KVUE Read-Through: Retailer destocking in May could create a shipment-vs.-consumption gap for KVUE in Q2, similar to the dynamic that caused revenue misses in 2024–2025. Watch for any commentary on consumption vs. shipments.
• China: Brick-and-Mortar Down, E-Commerce Offsetting: CL described China as "fascinating" with the overall market "probably down 1% to 2% in total," with brick-and-mortar declining and e-commerce partially offsetting. KVUE Read-Through: KVUE's Asia Pacific segment ($700M in Q1 2026) has been a persistent headwind. CL's China commentary suggests the market remains challenged but is not deteriorating further — a modest positive for KVUE's APAC trajectory.

Procter & Gamble (PG) — Q4 FY2026 Earnings Call (July 29, 2026)

Relevance to KVUE: PG is the largest consumer staples peer and competes with KVUE in personal care, baby care, and oral care. PG's FY2027 guidance (calendar 2H 2026 – 1H 2027) and commentary on consumer behavior, pricing, and input costs are highly relevant to KVUE's 2H 2026 trajectory.

• Volatile and Challenging Environment Ahead: PG guided FY2027 organic sales growth of 1%–3% and core EPS growth of 0%–3%, citing "volatile and challenging" conditions from "costs to currencies to consumer, competitor, retailer and geopolitical dynamics." PG expects a ~$1B after-tax cost headwind in FY2027 from higher raw materials, energy, transportation, and tariffs, with "most of this impact felt in the first half of fiscal '27" (i.e., calendar 2H 2026). KVUE Read-Through: PG's cost headwind commentary is directly relevant to KVUE's 2H 2026 gross margin outlook. If PG — with its scale and procurement advantages — is absorbing a $1B cost headwind, KVUE's smaller scale makes it more vulnerable to similar pressures.
• Consumer Bifurcation: Discernment, Not Inability to Buy: PG observed that higher-income consumers "continue to behave as they behaved before" while more pressured consumers "continue to look for smaller pack sizes" and are "very affected by promotion patterns." PG characterized this as "a little more of discernment by consumers, not an inability to buy." KVUE Read-Through: KVUE's brands (Tylenol, Neutrogena, Listerine) skew toward the mid-to-premium tier. PG's framing suggests demand is intact but promotional sensitivity is elevated — consistent with KVUE's need to balance pricing and volume in Self Care.
• Promotion Returning to Pre-COVID Levels: PG noted "promotion increasing back to pre-COVID levels" with "Europe volume on promotion up about 5 points in the most recent read." PG expects both the U.S. and Europe to "over time return to pre-COVID promotion levels." KVUE Read-Through: Rising promotional intensity is a headwind to KVUE's pricing/value realization. KVUE's Q1 2026 organic growth was driven by +1.0% value realization — if the promotional environment intensifies in Q2, this tailwind could moderate.
• Higher Growth Expected in Beauty & Health Segments: PG stated it expects "higher growth rates in segments like Beauty and Health" and plans to "accelerate that part of the portfolio." KVUE Read-Through: Constructive for KVUE's Skin Health & Beauty segment (Neutrogena, Aveeno, OGX), which delivered +5.0% organic growth in Q1 2026. PG's commentary validates the category tailwind.
• Retailer Inventory Volatility Expected to Continue: PG acknowledged "there's going to be some level of trade inventory volatility quarter-over-quarter" and noted that retailers tend to "unstock and restock P&G" given its high velocity. KVUE Read-Through: Inventory volatility is a recurring risk for KVUE, which has historically seen shipment-vs.-consumption gaps. Q2 2026 could see some inventory normalization benefit after May destocking.

Church & Dwight (CHD) — Q2 2026 Earnings Release (July 31, 2026)

Relevance to KVUE: CHD competes with KVUE in oral care (THERABREATH vs. Listerine), personal care, and household products. CHD's raised full-year guidance and commentary on volume-led growth and gross margin expansion are a constructive read-through for KVUE's category dynamics.

• Raised Full-Year Guidance — Volume-Led Growth: CHD raised FY2026 organic sales growth guidance to +4%–5% (from +3%–4%) and adj. EPS growth to +6%–8% (from +5%–8%), citing "volume growth, market share gains and gross margin expansion." CHD also raised adj. gross margin guidance to +100–120 bps expansion for the full year. KVUE Read-Through: CHD's raised guidance is a positive signal for consumer staples category health. Volume-led growth is constructive for KVUE's Q2 organic sales trajectory, particularly in Skin Health & Beauty where KVUE also saw volume-driven growth in Q1 (+4.2% volume).
• Gross Margin Expansion Despite Tariff Headwinds: CHD expects full-year adj. gross margin to expand +100–120 bps, with "volume growth, productivity, and favorable mix from acquisitions and portfolio actions" expected to "fully offset inflation, transportation and tariff-related costs." CHD also expects ~$15M in Phase II tariff refund benefits in 2H 2026. KVUE Read-Through: CHD's ability to expand gross margins despite tariff headwinds is a constructive template for KVUE, which is pursuing similar productivity savings through its 2026 Restructuring Initiative. However, CHD's tariff refund benefit is a one-time item not available to KVUE.
• Innovation as Key Growth Driver: CHD noted that "new product launches this year are expected to account for approximately half of our organic growth" and highlighted THERABREATH toothpaste momentum and new rinse innovations. Marketing spending is expected to increase to ~12% of sales in Q3. KVUE Read-Through: KVUE's Q1 2026 growth was also innovation-driven (Listerine global restage, OGX Pro Growth, Neutrogena Sun Care expansion). CHD's commentary validates the innovation-led growth strategy in oral care and personal care categories.
• Middle East Inflation Manageable: CHD acknowledged that "the situation in the Middle East creates some inflationary pressure" but expects to "offset this transitory cost pressure in 2026." KVUE Read-Through: Consistent with KVUE's Q1 commentary that productivity gains are offsetting inflation and tariffs. The "transitory" framing is more optimistic than PG's $1B headwind guidance, suggesting company-specific execution matters more than macro.

Newell Brands (NWL) — Q2 2026 Earnings Call (July 31, 2026)

Relevance to KVUE: NWL is a broader consumer products peer with exposure to similar retail channels and consumer income cohorts. NWL's commentary on consumer bifurcation, input cost inflation, and category dynamics provides useful context for KVUE's North America business.

• Low-Income Consumer Stabilizing: NWL noted that "the low income consumer, which had been running down more, is now annualizing that. So they seem to be stabilizing and their year over year decline is reducing." The high-income consumer continues to drive "mid-single digit growth" in general merchandise, while the middle-income consumer is "relatively flat to down low single digits." KVUE Read-Through: Stabilization of the low-income consumer is a modest positive for KVUE's Essential Health segment (Band-Aid, Listerine, baby care), which serves a broader income demographic. Self Care (Tylenol, Zyrtec) skews more toward mid-to-high income consumers.
• Input Cost Inflation Significantly Higher Than Expected: NWL now expects ~$200M in inflationary impacts for 2026 (vs. initial $100M expectation), with ~$50M of the increase occurring since the last earnings call. NWL expects $127M in net tariff headwinds for 2026. However, NWL believes "some of this inflation might be peak inflation" with resin prices beginning to roll down. KVUE Read-Through: NWL's inflation escalation is a cautionary signal for KVUE's cost structure. While KVUE's product mix (OTC healthcare, personal care) differs from NWL's (housewares, writing), both face similar raw material and tariff pressures. KVUE's productivity program is the key offset.
• Mid/Premium Tier Growing Faster Than Opening Price Point: NWL noted that "the mid and the premium tier parts of the market are actually growing faster than the opening price point part of the market" and focused its innovation at the mid-to-upper tier. KVUE Read-Through: Constructive for KVUE's Skin Health & Beauty segment, which is positioned at the mid-to-premium tier (Neutrogena, Aveeno). Less relevant for Self Care, where Tylenol competes against private-label alternatives.
• Selective Pricing Rather Than Broad-Based Actions: NWL has taken "selective and targeted" pricing actions on resin-oriented products (~10% of business) but believes the tariff refund and productivity savings "negate the need for broad-based pricing actions." NWL is monitoring the situation and may enact future pricing if conditions worsen. KVUE Read-Through: KVUE's Q1 2026 organic growth included +1.0% value realization. NWL's selective pricing approach mirrors KVUE's revenue growth management strategy. The risk is that broad-based pricing becomes necessary in 2H if tariff headwinds intensify as CL and PG suggest.

Peer Read-Through Summary Table

Sources: Colgate-Palmolive Q2 2026 Earnings Call Transcript (July 31, 2026); Procter & Gamble Q4 FY2026 Earnings Call Transcript (July 29, 2026); Church & Dwight Q2 2026 Earnings Release (July 31, 2026); Newell Brands Q2 2026 Earnings Call Transcript (July 31, 2026). All commentary is forward-looking, applicable to Q2 2026 or beyond, and disclosed after KVUE's last earnings (May 7, 2026).

Appendix: Key Risks & Considerations

• Merger Closing Risk: The KMB deal remains subject to foreign regulatory approvals. Any delay or challenge to closing would likely cause KVUE to trade back toward standalone fundamental value (~$15–$17 range based on pre-deal trading), representing ~15–25% downside from current levels.
• Guidance Vacuum: With no forward guidance and no earnings call, investors have limited visibility into management's view of 2H 2026 trends. Any negative surprise in Q2 results (particularly organic sales or gross margin) would have outsized impact given the absence of a guidance anchor.
• Tariff Escalation: If tariff headwinds intensify beyond current peer commentary (CL, PG flagging 2H peak), KVUE's gross margin expansion trajectory could reverse, particularly given the $250M restructuring charge burden in FY2026.
• Self Care Seasonality: Q2 is typically a weaker quarter for Self Care (cold/flu off-season). Allergy season (Zyrtec) is the key offset. A below-average allergy season or continued consumer trade-down to private label could pressure Self Care organic growth.
• Skin Health & Beauty Sustainability: Q1 2026's +5.0% organic growth in Skin H&B was the strongest in several quarters. Sustaining this momentum in Q2 requires continued eCommerce acceleration and EMEA/LatAm strength. Any deceleration would be a negative surprise given elevated consensus expectations.
• Litigation Overhang: Tylenol/autism litigation claims remain an unresolved liability. While not an immediate earnings catalyst, any adverse legal development could complicate the KMB merger closing or create incremental financial exposure.